Intraosseous needle for management of subacute and chronic subdural hematoma.

IF 3.6 2区医学 Q1 CLINICAL NEUROLOGY

Journal of neurosurgery Pub Date : 2025-05-02 DOI:10.3171/2025.1.JNS241265

Navraj Heran, Tyler D Yan, Manraj K S Heran, Amir Behboudi, Susan K Kadyschuk

{"title":"Intraosseous needle for management of subacute and chronic subdural hematoma.","authors":"Navraj Heran, Tyler D Yan, Manraj K S Heran, Amir Behboudi, Susan K Kadyschuk","doi":"10.3171/2025.1.JNS241265","DOIUrl":null,"url":null,"abstract":"Objective: The primary objective of this study was to evaluate the safety and efficacy of using an intraosseous (IO) needle for decompressive management of subacute and chronic subdural hematomas (SDHs).Methods: This is a single-center retrospective review of subacute and chronic SDHs treated with IO needle decompression from May 2022 to November 2023. Technical success, recurrence, procedure-related complications, major adverse events, patient demographics, and procedural details were analyzed using standard statistical analysis.Results: Fifty-one patients (mean age 75.4 [SD 11.4] years) met the inclusion criteria. Technical success was achieved in all patients, with only 1 case of recurrence. Rates of procedure-related complications (3/51, 5.9%) and major adverse events (2/51, 4%) were low. There were no statistically significant differences between those with subacute SDHs compared with those with chronic SDHs.Conclusions: IO needle decompression is a feasible, safe, and effective option for management of subacute and chronic SDHs, with minimal recurrence.","PeriodicalId":16505,"journal":{"name":"Journal of neurosurgery","volume":" ","pages":"1-8"},"PeriodicalIF":3.6000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3171/2025.1.JNS241265","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The primary objective of this study was to evaluate the safety and efficacy of using an intraosseous (IO) needle for decompressive management of subacute and chronic subdural hematomas (SDHs).

Methods: This is a single-center retrospective review of subacute and chronic SDHs treated with IO needle decompression from May 2022 to November 2023. Technical success, recurrence, procedure-related complications, major adverse events, patient demographics, and procedural details were analyzed using standard statistical analysis.

Results: Fifty-one patients (mean age 75.4 [SD 11.4] years) met the inclusion criteria. Technical success was achieved in all patients, with only 1 case of recurrence. Rates of procedure-related complications (3/51, 5.9%) and major adverse events (2/51, 4%) were low. There were no statistically significant differences between those with subacute SDHs compared with those with chronic SDHs.

Conclusions: IO needle decompression is a feasible, safe, and effective option for management of subacute and chronic SDHs, with minimal recurrence.

查看原文本刊更多论文

骨内针治疗亚急性和慢性硬膜下血肿。

目的：本研究的主要目的是评估使用骨内针（IO）减压治疗亚急性和慢性硬膜下血肿（SDHs）的安全性和有效性。方法：这是一项从2022年5月至2023年11月间采用IO针减压治疗亚急性和慢性sdh的单中心回顾性研究。技术成功、复发、手术相关并发症、主要不良事件、患者人口统计学和手术细节采用标准统计分析进行分析。结果：51例患者（平均年龄75.4 [SD 11.4]岁）符合纳入标准。所有患者均取得技术上的成功，仅有1例复发。手术相关并发症（3/51,5.9%）和主要不良事件（2/51,4%）发生率较低。亚急性sdh组与慢性sdh组比较，差异无统计学意义。结论：IO针减压是治疗亚急性和慢性sdh的一种可行、安全、有效的选择，复发率最低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of neurosurgery 医学-临床神经学

CiteScore

7.20

自引率

7.30%

发文量

1003

审稿时长

1 months

期刊介绍： The Journal of Neurosurgery, Journal of Neurosurgery: Spine, Journal of Neurosurgery: Pediatrics, and Neurosurgical Focus are devoted to the publication of original works relating primarily to neurosurgery, including studies in clinical neurophysiology, organic neurology, ophthalmology, radiology, pathology, and molecular biology. The Editors and Editorial Boards encourage submission of clinical and laboratory studies. Other manuscripts accepted for review include technical notes on instruments or equipment that are innovative or useful to clinicians and researchers in the field of neuroscience; papers describing unusual cases; manuscripts on historical persons or events related to neurosurgery; and in Neurosurgical Focus, occasional reviews. Letters to the Editor commenting on articles recently published in the Journal of Neurosurgery, Journal of Neurosurgery: Spine, and Journal of Neurosurgery: Pediatrics are welcome.